Exceptional Circumstances and Named Patient Pharmaceutical Assessment
Named Patient Pharmaceutical Assessment
Beginning 1 March 2012, PHARMAC’s Exceptional Circumstances (EC) Policy was replaced by the Named Patient Pharmaceutical Assessment (NPPA) Policy. For more information on the NPPA Policy, including the prerequisite requirements, decision criteria, how to apply, and background on the development of NPPA, click here. Please be sure to update the web addresses in your Internet browser's "Favourites" folder.
Patients approved for EC funding prior to 1 March 2012 will continue to receive funding for their treatment and will be considered for renewal funding (where applicable) according to any renewal conditions outlined in their EC approval.
Exceptional Circumstances
To find out more about EC renewals, read the Exceptional Circumstances Information Sheet (6 pages, 115 KB).
To apply for renewal of funding for an application approved under EC, download the relevant form below:
- Community Exceptional Circumstances renewal form (2 pages, 134 KB)
- Cancer Exceptional Circumstances renewal form (3 pages, 80 KB)
- Hospital Exceptional Circumstances renewal form (4 pages, 159 KB)
Exceptional Circumstances Panel
Exceptional Circumstances renewal applications will be considered by the NPPA Advisory Panel.
Other application forms
- Special Authority applications
- Prednisolone sodium phosphate oral liquid (3 pages, 62 KB)
- Alpha tocopheryl acetate (3 pages, 123 KB)
- PCT Paediatric Oncology/Haematology Notification Form (1 page, 18 KB)
Page updated on 02 May 2012
Linked documents
Exceptional Circumstances information sheet (6 pages, 115 KB)
INFORMATION SHEET FOR COMMUNITY, HOSPITAL AND CANCER EXCEPTIONAL CIRCUMSTANCES Beginning 1 March 2012, PHARMAC’s Exceptional Circumstances (EC) Policy was replaced by the Named Patient Pharmaceutical Assessment (NPPA) Policy. Patients approved for EC funding prior to 1 March 2012 will continue…
Application form for renewal of Community Exceptional Circumstances (2 pages, 134 KB)
Application Form for RENEWAL of Community Exceptional Circumstances Approval Return completed form to: Panel Co-ordinator PHARMAC PO Box 10-254, Wellington Phone: 04-916-7553 Fax: 09-523-6870 Email: ecpanel@pharmac.govt.nz Please refer to the information sheet if necessary. Complete ALL relevant details. Please type…
Cancer Exceptional Circumstances renewal form (3 pages, 80 KB)
Application Form for RENEWAL of Cancer Exceptional Circumstances Approval Return completed form to: Co-ordinator PHARMAC PO Box 10-254 Wellington Phone Fax: Email: 04-916-7553 09-523-6870 ecpanel@pharmac.govt.nz (note: fax number redirects to Wgtn office) 1. ELIGIBILITY UNDER CANCER EXCEPTIONAL CIRCUMSTANCES POLICY In…
Application form for renewal of Hospital Exceptional Circumstances (4 pages, 159 KB)
Return completed form to: Fax: 09 523 6870 (preferred) Application Form for RENEWAL of Hospital Exceptional Circumstances Panel Co-ordinator PO Box 10-254, Wellington Phone: 04-916-7553 Email: ecpanel@pharmac.govt.nz Please refer to the information sheet if necessary. Complete ALL relevant details. Please…
Application for prednisolone sodium phosphate oral liquid (3 pages, 62 KB)
APPLICATION INFORMATION FOR PREDNISOLONE SODIUM PHOSPHATE ORAL LIQUID With the withdrawal of the GSK’s brand of betamethasone (Betnesol) 0.5mg dispersable tablet from the market, an alternative oral corticosteroid is available for patients over 12 years of age from Aventis, prednisolone…
Information and application form for alpha tocopheryl acetate (3 pages, 123 KB)
Information Sheet for Alpha Tocopheryl Acetate Alpha tocopheryl acetate (Micelle E) has been delisted from the Pharmaceutical Schedule from 1 June 2011, as the supplier of this product has withdrawn from the New Zealand market. Until such time as PHARMAC…
PCT Paediatric Oncology/Haematology Notification Form (1 page, 18 KB)
Pharmaceutical Cancer Treatments Paediatric Oncology/Haematology Notification Form Return completed form to: Panel Coordinator, PHARMAC Phone: Fax: 04 916 7553 09 523 6870 Patient details Last name First name Date of birth NHI number Prescribing practitioner details Last name First name…
